AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Remotely-Activated Cell-based Immunotherapy

Technology Application

This patent-pending technology therefore potentially allows controlled, rapid, remote cell activation for targeted immunotherapy.

Detailed Technology Description

Researchers at UC San Diego developed a technology that offers controllable cellular therapeutic activation of engineered T-cells, using a method of remote stimulation. Localization of therapeutic efficacy, even deep within the body, may be provided by this technology, and with spatiotemporal precision and the limitation of off-target effects. The ability to activate desired T-cell functions, and to do so within a prescribed therapeutic area, is a significant new modality for therapeutics. Upon delivery of the cells, and the targeted stimulus, a broad range of pre-programmed cellular activities and functions can be initiated. The method of cellular stimulation is based on widely-adopted medically-approved medical device technology that is non-invasive, and safe. The stimulus itself has minimal effect on the surrounding tissues, and so tunable therapy without invasive surgery is provided by the ability to directly apply the triggering signal to a localized area, and from a remote position.

Others

Related Technologies

Remotely-Activated Cell Therapy

Tech ID/UC Case

27470/2017-019-0

Related Cases

2017-019-0

Country/Region

USA

For more information, please click Here